Pharmaguy™’s Twitter Stream – Q2 2009

Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News

AMA Struggles to Reign in Consumer Drug Ads

You have to give kudos to the good doctors and policy makers of the American Medical Association for trying over the course of many to ban or in some way curtail direct-to-consumer drug ads by pharmaceutical companies. The latest effort focuses on drug price transparency in ads. Will it succeed where the other efforts have failed?

Pharmaguy™

Pharmaguy™ is a Pharma Marketing 'Constructive' Critic, Blogger & Chief Pundit at Pharmaguy.com

Peter Kirk: Sermo vs. Doximity = “Facebook” vs. “LinkedIn” for Docs

In this 3-minute audio snippet, Peter Kirk, CEO, Sermo, talks about the differences between Doximity and Sermo with regard to online physician discussions and the benefits of anonymity.

Pharmaguy’s Social Media Timeline

Pharmaguy's Social Media Timeline

Tom Stossel: Debunking the “Conflict-of-Interest Narrative”

In this 5-minute audio snippet, Thomas P. Stossel, M.D., visiting scholar at the American Enterprise Institute for Public Policy Research, talks about what he calls the 'Conflict-of-Interest Narrative' or Myth, which is the subject of his new book, PharmaPhobia.

Shona Davies and Sean Nicholson: How Do You Define “Engagement?”

In this 3-minute audio snippet, Shona L. Davies, Communications & Programme Leader, Univadis, and Sean Nicholson, Senior Director, Social Media, Intouch Solutions, define what they mean by social media

Pharmaguy™’s Twitter Stream – Q4 2009

Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News

5-Minute Audio Podcasts

Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News

Ambre Morley: Vetting Celebrity Spokespersons to Ensure Return on Investment

In this 2-minute audio snippet, Ambre Morley, Associate Director, Product Communications, Novo Nordisk, talks about vetting Paula Deen as a paid celebrity spokesperson for the Novo Victoza diabetes drug franchise and the importance of measuring celebrity return on investment (ROI).
- Advertisement -